UPA IpamoreliniPamorelin iPamorelin is a GHRP (Growth Hormone Releasing Peptide) that is considered one of the mildest due to it being perhaps the most side effect friendly of the GHRP hormones. iPamorelin was first developed by Novo Nordisk and made its way to phase two clinical trials through Helsinn Therapeutics. However, while it showed promising results the full trials were never completed and the project was scrapped. Although it is not found in medical